Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date16 Feb 1978 |
100 Clinical Results associated with Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.
100 Deals associated with Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.